[go: up one dir, main page]

PE20240144A1 - Inhibidores de mk2 y usos de estos - Google Patents

Inhibidores de mk2 y usos de estos

Info

Publication number
PE20240144A1
PE20240144A1 PE2023002765A PE2023002765A PE20240144A1 PE 20240144 A1 PE20240144 A1 PE 20240144A1 PE 2023002765 A PE2023002765 A PE 2023002765A PE 2023002765 A PE2023002765 A PE 2023002765A PE 20240144 A1 PE20240144 A1 PE 20240144A1
Authority
PE
Peru
Prior art keywords
disorders
nrcrd
ora
ring
heteroaryl
Prior art date
Application number
PE2023002765A
Other languages
English (en)
Inventor
Lynnie Trzoss
Qing Dong
Stephen W Kaldor
Robert L Hoffman
Original Assignee
Xinthera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xinthera Inc filed Critical Xinthera Inc
Publication of PE20240144A1 publication Critical patent/PE20240144A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta referido a un compuesto de Formula II, en donde: anillo A es fenilo o heteroarilo; anillo B es heterocicloalquilo o heteroarilo; anillo C es heteroarilo de 5 miembros; R1 y R2 son -CN, -NO2, -OH, -ORa, entre otros; R5 es H, deuterio, -CN, -NO2, -OH, entre otros; R6 es -OH, -ORa, -NRcRd, -C(=O)Ra, entre otros; R7 es -ORa, -NRcRd, -C(=O)Ra, -C(=O)ORb, entre otros; RA es H, halogeno, CN, NO2, OH, entre otros; RB es halogeno, -CN, -NO2, -OH, entre otros; RC es -OC(=O)NRcRd, -SH, -SRa, -S(=O)Ra, -S(=O)2Ra, entre otros; X es -C(R3 )2-, -NR4 -, -O- o -S-; m es un numero entre 0 y 4; y n es un numero entre 0 y 4. Estos compuestos son inhibidores de MK2 y son utiles en el tratamiento de trastornos autoinmunitarios, trastornos inflamatorios cronicos, trastornos inflamatorios agudos, trastornos autoinflamatorios, trastornos fibroticos, trastornos metabolicos, trastornos neoplasicos o trastornos cardiovasculares o cerebrovasculares.
PE2023002765A 2021-03-31 2022-03-30 Inhibidores de mk2 y usos de estos PE20240144A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163168407P 2021-03-31 2021-03-31
US202263318118P 2022-03-09 2022-03-09
PCT/US2022/022525 WO2022212489A1 (en) 2021-03-31 2022-03-30 Mk2 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
PE20240144A1 true PE20240144A1 (es) 2024-02-01

Family

ID=83459911

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023002765A PE20240144A1 (es) 2021-03-31 2022-03-30 Inhibidores de mk2 y usos de estos

Country Status (16)

Country Link
US (3) US11680056B2 (es)
EP (1) EP4313970A4 (es)
JP (1) JP2024512154A (es)
KR (1) KR20230163501A (es)
AU (1) AU2022252242A1 (es)
BR (1) BR112023019861A2 (es)
CA (1) CA3215746A1 (es)
CL (1) CL2023002921A1 (es)
CO (1) CO2023013150A2 (es)
CR (1) CR20230468A (es)
DO (1) DOP2023000212A (es)
IL (1) IL307187A (es)
MX (1) MX2023011503A (es)
PE (1) PE20240144A1 (es)
TW (1) TW202304879A (es)
WO (1) WO2022212489A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023019861A2 (pt) 2021-03-31 2023-11-07 Xinthera Inc Inibidores de mk2 e usos dos mesmos
AU2022307534A1 (en) 2021-07-09 2024-02-22 Xinthera, Inc. Pyridinone mk2 inhibitors and uses thereof
TWI866007B (zh) * 2021-12-29 2024-12-11 大陸商上海美悦生物科技發展有限公司 p38 MAPK/MK2通路調節劑及其組合物、製備方法和用途
CN116444492A (zh) * 2021-12-29 2023-07-18 上海美悦生物科技发展有限公司 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途
CN116396274A (zh) * 2022-01-06 2023-07-07 深圳信立泰药业股份有限公司 一种取代的联吡啶酮类化合物及其制备方法与应用
CN116425722A (zh) * 2022-01-13 2023-07-14 深圳信立泰药业股份有限公司 一种取代的联吡啶酮-芳(杂)环类化合物及其制备方法与应用
CN116444493A (zh) * 2022-01-14 2023-07-18 上海翰森生物医药科技有限公司 含双并环类衍生物、其制备方法和应用
WO2023217184A2 (zh) * 2022-05-12 2023-11-16 上海美悦生物科技发展有限公司 取代的吡啶或嘧啶类衍生物及其药物组合物、制备方法和用途
TW202412792A (zh) * 2022-08-30 2024-04-01 大陸商長春金賽藥業有限責任公司 ｐ３８α－ＭＫ２抑制劑化合物、藥物組合物及其用途
TW202430516A (zh) * 2022-10-05 2024-08-01 美商辛瑟拉股份有限公司 Ｍｋ２抑制劑之晶形
TW202428271A (zh) * 2022-11-16 2024-07-16 大陸商上海美悦生物科技發展有限公司 吡啶氮氧化物類衍生物及其藥物組合物、製備方法和用途
WO2024149359A1 (zh) * 2023-01-13 2024-07-18 上海美悦生物科技发展有限公司 苯基取代的杂芳基类化合物及其药物组合物、制备方法和用途
WO2025002076A1 (zh) * 2023-06-26 2025-01-02 深圳信立泰药业股份有限公司 一种mk2抑制剂在制备预防和/或治疗疾病药物中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA008008B1 (ru) * 2002-02-14 2007-02-27 Фармация Корпорейшн Замещённые пиридиноны в качестве модуляторов мар-киназы р38
US7183287B2 (en) * 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
US20070167621A1 (en) * 2003-04-03 2007-07-19 Pharmacia Corporation Substituted pyrimidinones
NL1026826C2 (nl) * 2003-08-13 2007-01-04 Pharmacia Corp Gesubstitueerde pyridinonen.
US20090270350A1 (en) * 2006-02-10 2009-10-29 Pfizer Inc. Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives
JP2010529129A (ja) * 2007-06-06 2010-08-26 タイロジェネックス，インコーポレイテッド キナーゼ阻害剤化合物
JP2012528869A (ja) 2009-06-03 2012-11-15 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー メラニン凝集ホルモン受容体１アンタゴニストとしてのビス−ピリジルピリドン類
US9359300B2 (en) 2010-12-06 2016-06-07 Confluence Life Sciences, Inc. Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
HUE040101T2 (hu) * 2010-12-06 2019-02-28 Aclaris Therapeutics Inc Szubsztituált piridinon-piridinil-származékok
WO2013033657A2 (en) 2011-09-02 2013-03-07 The Trustees Of Columbia University In The City Of New York CaMKII, IP3R, CALCINEURIN, P38 AND MK2/3 INHIBITORS TO TREAT METABOLIC DISTURBANCES OF OBESITY
WO2013086208A1 (en) 2011-12-06 2013-06-13 Confluence Life Sciences, Inc. Substituted pyrimidinone-phenyl-pyrimidinyl compounds
US9365540B2 (en) * 2012-01-12 2016-06-14 Takeda Pharmaceutical Company Limited Benzimidazole derivatives as MCH receptor antagonists
PT3003039T (pt) * 2013-06-07 2021-03-04 Aclaris Therapeutics Inc Compostos piridinona-piridinilo substituídos com metil/fluoro-piridinil-metoxilo e compostos piridinona-pirimidinilo substituídos com fluoro-pirimidinil-metoxilo
PH12022550029A1 (en) 2019-07-31 2023-02-27 Aclaris Therapeutics Inc Deuterated mk2 pathway inhibitors and methods of using the same
KR20220161396A (ko) 2020-03-27 2022-12-06 어클라리스 쎄라퓨틱스, 인코포레이티드 치환된 피리디논-피리디닐 화합물의 제조, 조성물, 및 결정형
WO2022081573A1 (en) * 2020-10-12 2022-04-21 University Of Tennessee Research Foundation Transient receptor potential canonical 3 inhibitors and methods of use thereof
CA3198300A1 (en) 2020-11-23 2022-05-27 Gary A. Decrescenzo Methods of synthesizing substituted pyridinone-pyridinyl compounds
CN116670142A (zh) 2021-02-01 2023-08-29 细胞基因公司 Mk2抑制剂、其合成和其中间体
KR20230152692A (ko) 2021-02-02 2023-11-03 리미널 바이오사이언시스 리미티드 Gpr84 길항제 및 이의 용도
BR112023019861A2 (pt) 2021-03-31 2023-11-07 Xinthera Inc Inibidores de mk2 e usos dos mesmos
US20230135894A1 (en) 2021-06-30 2023-05-04 Kymera Therapeutics, Inc. Mk2 degraders and uses thereof
AU2022307534A1 (en) 2021-07-09 2024-02-22 Xinthera, Inc. Pyridinone mk2 inhibitors and uses thereof
WO2023001282A1 (zh) 2021-07-23 2023-01-26 南京明德新药研发有限公司 杂环取代的嘧啶衍生物
TW202315625A (zh) 2021-08-13 2023-04-16 大陸商深圳信立泰藥業股份有限公司 三聯吡啶二酮化合物或其鹽、包括其藥物組合物及其用途
CN116178345B (zh) 2021-10-19 2024-08-13 深圳信立泰药业股份有限公司 一种取代的嘧啶基-吡啶基-吡啶酮化合物及其制备方法与应用
TWI866007B (zh) 2021-12-29 2024-12-11 大陸商上海美悦生物科技發展有限公司 p38 MAPK/MK2通路調節劑及其組合物、製備方法和用途
CN116444492A (zh) 2021-12-29 2023-07-18 上海美悦生物科技发展有限公司 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途
CN115636814A (zh) 2022-02-28 2023-01-24 瑞石生物医药有限公司 一种嘧啶衍生物及其用途

Also Published As

Publication number Publication date
CL2023002921A1 (es) 2024-04-01
DOP2023000212A (es) 2023-11-30
US11680056B2 (en) 2023-06-20
TW202304879A (zh) 2023-02-01
EP4313970A1 (en) 2024-02-07
MX2023011503A (es) 2023-10-19
US20220402892A1 (en) 2022-12-22
BR112023019861A2 (pt) 2023-11-07
KR20230163501A (ko) 2023-11-30
WO2022212489A1 (en) 2022-10-06
US20230265076A1 (en) 2023-08-24
CR20230468A (es) 2023-12-07
CO2023013150A2 (es) 2024-02-05
CA3215746A1 (en) 2022-10-06
US11987574B2 (en) 2024-05-21
IL307187A (en) 2023-11-01
US20230373969A1 (en) 2023-11-23
EP4313970A4 (en) 2025-06-25
JP2024512154A (ja) 2024-03-18
AU2022252242A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
PE20240144A1 (es) Inhibidores de mk2 y usos de estos
CH431310A (fr) Procédé de traitement des surfaces de frottement de deux pièces métalliques
FR851194A (fr) Procédé de mise en ceuvre des fours siemens-martin
BR7100945D0 (pt) Tratamento integrado de aguas residuarias para aplicacao apos banhos de cianato
FR1270638A (fr) Procédé d'amélioration du rendement des sources d'éclairage dites
JP1768030S (ja) 照明器具
FR1242945A (fr) Procédé de fixation du culot des lampes d'éclairage
FR685241A (fr) Procédé d'éclairage à grand rendement
FR52989E (fr) Procédé d'épuration d'eaux résiduaires
FR847445A (fr) Dispositif améliorant le rendement propulsif des bateaux
TR201800923A2 (tr) Mermer plakalarında epoksi ve file üzerine granül uygulaması
RU2015156305A (ru) Система для архитектурной подсветки объектов деревянного зодчества с многоуровневым резным декором
BR7204071D0 (pt) Processo para purificacao de uma solucao de sulfato de zinco contendo ferro
Roura-Parella Wiese
FR905401A (fr) Application nouvelle d'un traitement thermique à la purification et l'enrichissement du sulfate de strontium naturel par l'élimination du carbonate de calcium
FR922309A (fr) Procédé de traitement du brai
FR878827A (fr) Procédé de purification du chlorure de zinc
FR883566A (fr) Dispositif de fixation aux raccords des extrémités des tuyaux métalliques flexibles et son procédé de fabrication
FR701529A (fr) Fabrication intensive du carbonate de magnésie léger et du carbonate de chaux léger et éventuellment de carbonate de potasse et de chlorure de magnésium au moyen dedolomie
FR868569A (fr) Procédé d'éclairage de défense passive et son utilisation dans la découverte et la poursuite des objectifs ennemis
FR857028A (fr) Procédé de fabrication de magnésie et de chaux en partant de la dolomie
AT174668B (de) Leuchte für eine oder mehrere rohrförmige Fluoreszenzlampen und Glühlampen
FR684400A (fr) Procédé d'obtention de nitriles aromatiques par traitement d'amines aromatiques avec des cyanures de cuivre bivalent
DK97243C (da) Trugformet belysningsarmatur af formstof.
RU2002130858A (ru) Резинометаллический анкер